Antibiotic Complexation with Saccharide and Metal Ion

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current treatments for tuberculosis, especially drug-resistant strains, are lengthy, costly, and have low efficacy due to poor delivery methods and resistance issues, necessitating the development of new strategies to enhance antibiotic effectiveness.

Innovation Solution

A tablet formulation combining a saccharide, a transition metal cation, and a water-soluble polymer to enhance the delivery and efficacy of existing antibiotics, specifically using sucrose, copper ions, and polyethylene glycol (PEG) to improve the bioavailability and stability of antibiotics like isoniazid and rifampin.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If traditional antibiotics are used to treat tuberculosis, then treatment can be provided, but efficacy is poor against drug-resistant strains and treatment duration is lengthy

Engineering Contradiction:
Improveantibiotic efficacyVSAvoidtreatment duration
Core Design Contradiction:
ReliabilityVSLoss of time

Solution Approach 1:

The patent creates a composite material consisting of an antibiotic molecule complexed with a saccharide and a transition metal cation. This composite structure enhances the antibiotic's ability to penetrate the mycolic acid-rich cell wall of Mycobacterium tuberculosis, thereby improving efficacy against both susceptible and drug-resistant strains while potentially shortening treatment duration.

Inventive Principle:
Principle #40Composite materials

Solution Approach 2:

The patent modifies the chemical parameters of the antibiotic by complexing it with a saccharide and transition metal cation. This changes the physical-chemical properties of the drug, including its solubility, stability, and ability to interact with the bacterial cell wall, thereby enhancing its effectiveness against drug-resistant strains.

Inventive Principle:
Principle #35Parameter changes

2Reliability

If higher dosages of antibiotics are administered to overcome resistance, then efficacy may improve, but side effects increase and treatment cost increases

Engineering Contradiction:
Improvetreatment efficacyVSAvoidside effects
Core Design Contradiction:
ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent changes the chemical parameters of the antibiotic through complexation with saccharide and transition metal cation, which enhances its ability to penetrate the bacterial cell wall. This allows lower dosages to achieve the same therapeutic effect, thereby reducing side effects and treatment costs while maintaining efficacy.

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The saccharide and transition metal cation act as intermediaries that facilitate the antibiotic's interaction with the bacterial cell wall. This intermediary complex improves drug delivery and penetration efficiency, allowing lower doses of the antibiotic to achieve effective concentrations at the target site.

Inventive Principle:
Principle #24Intermediary (Mediator)

3Quantity of substance

If existing antibiotics are used without modification, then treatment is economical, but they cannot effectively penetrate the mycolic acid-rich cell wall of M. tuberculosis

Engineering Contradiction:
Improvedrug penetration efficiencyVSAvoidformulation complexity
Core Design Contradiction:
Quantity of substanceVSDevice complexity

Solution Approach 1:

The patent develops a composite material where the antibiotic is complexed with a saccharide and transition metal cation. This composite structure enhances penetration of the mycolic acid-rich cell wall while maintaining relative simplicity in formulation and administration.

Inventive Principle:
Principle #40Composite materials

Solution Approach 2:

The patent applies local quality modification by specifically targeting the cell wall interface. The saccharide and transition metal cation complex localizes at the bacterial cell wall, creating a localized enhancement of penetration capability without requiring modification of the entire drug delivery system.

Inventive Principle:
Principle #3Local quality

Data Source

PatentEP3331504B1Tablet composition for Anti-tuberculosis antibiotics
Publication Date: 2024.08.28 MANNING THOMAS
  • EP3331504B1 patent drawingFigure 1~1B
  • EP3331504B1 patent drawingFigure 2
  • EP3331504B1 patent drawingFigure 3

AI summary

Bacterial resistance to antibiotics is increasing worldwide creating a global threat. Tuberculosis (TB), caused by the bacterium Mycobacterium tuberculosis, is a bacterial infectious disease that results in over one million deaths annually. The discovery outlined here involves a tablet composition for patient administration and subsequently a new paradigm in drug delivery vehicles in vivo and in vitro and is applied to existing TB antibiotics in order to increase their efficacy. The drug delivery system is a three component complex that is administered with the TB antibiotic or a combination of TB antibiotics. The components are a saccharide or saccharides, a transition metal ion or a combination of metal ions that can bind a nitrogen and/or oxygen atom(s), and a water soluble polymer capable of aggregating and enclosing the other constituents! The three component molecular delivery approach has demonstrated ability to overcome M. tuberculosis bacterial resistance to an existing antibiotic.